301 related articles for article (PubMed ID: 33115528)
21. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ
Int J Cancer; 2000 Sep; 87(5):688-94. PubMed ID: 10925363
[TBL] [Abstract][Full Text] [Related]
22. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.
Morales JK; Kmieciak M; Graham L; Feldmesser M; Bear HD; Manjili MH
Cancer Immunol Immunother; 2009 Jun; 58(6):941-53. PubMed ID: 18979098
[TBL] [Abstract][Full Text] [Related]
24. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.
Marshall JC; Collins JW; Nakayama J; Horak CE; Liewehr DJ; Steinberg SM; Albaugh M; Vidal-Vanaclocha F; Palmieri D; Barbier M; Murone M; Steeg PS
J Natl Cancer Inst; 2012 Sep; 104(17):1306-19. PubMed ID: 22911670
[TBL] [Abstract][Full Text] [Related]
25. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
Unitt E; Rushbrook SM; Marshall A; Davies S; Gibbs P; Morris LS; Coleman N; Alexander GJ
Hepatology; 2005 Apr; 41(4):722-30. PubMed ID: 15791620
[TBL] [Abstract][Full Text] [Related]
26. Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.
Kmieciak M; Morales JK; Morales J; Bolesta E; Grimes M; Manjili MH
Cancer Immunol Immunother; 2008 Sep; 57(9):1391-8. PubMed ID: 18278493
[TBL] [Abstract][Full Text] [Related]
27. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
[TBL] [Abstract][Full Text] [Related]
28. Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat.
Quan N; Zhang Z; Demetrikopoulos MK; Kitson RP; Chambers WH; Goldfarb RH; Weiss JM
Cancer Res; 1999 Mar; 59(5):1080-9. PubMed ID: 10070966
[TBL] [Abstract][Full Text] [Related]
29. CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer.
Kmieciak M; Worschech A; Nikizad H; Gowda M; Habibi M; Depcrynski A; Wang E; Godder K; Holt SE; Marincola FM; Manjili MH
Breast Cancer Res Treat; 2011 Apr; 126(2):385-94. PubMed ID: 20480224
[TBL] [Abstract][Full Text] [Related]
30. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.
Lan Q; Peyvandi S; Duffey N; Huang YT; Barras D; Held W; Richard F; Delorenzi M; Sotiriou C; Desmedt C; Lorusso G; Rüegg C
Oncogene; 2019 Apr; 38(15):2814-2829. PubMed ID: 30546090
[TBL] [Abstract][Full Text] [Related]
31. CD39
Tallón de Lara P; Castañón H; Vermeer M; Núñez N; Silina K; Sobottka B; Urdinez J; Cecconi V; Yagita H; Movahedian Attar F; Hiltbrunner S; Glarner I; Moch H; Tugues S; Becher B; van den Broek M
Nat Commun; 2021 Feb; 12(1):769. PubMed ID: 33536445
[TBL] [Abstract][Full Text] [Related]
32. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
33. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.
Tabariès S; Ouellet V; Hsu BE; Annis MG; Rose AA; Meunier L; Carmona E; Tam CE; Mes-Masson AM; Siegel PM
Breast Cancer Res; 2015 Mar; 17(1):45. PubMed ID: 25882816
[TBL] [Abstract][Full Text] [Related]
34. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals".
Manjili MH; Arnouk H; Knutson KL; Kmieciak M; Disis ML; Subjeck JR; Kazim AL
Breast Cancer Res Treat; 2006 Apr; 96(3):233-41. PubMed ID: 16211331
[TBL] [Abstract][Full Text] [Related]
35. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.
Campbell MJ; Wollish WS; Lobo M; Esserman LJ
In Vitro Cell Dev Biol Anim; 2002 Jun; 38(6):326-33. PubMed ID: 12513120
[TBL] [Abstract][Full Text] [Related]
36. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of tumor-infiltrating lymphocytes in the treatment of hepatic metastases arising from transgenic intraocular tumors in mice.
Ma D; Niederkorn JY
Invest Ophthalmol Vis Sci; 1995 May; 36(6):1067-75. PubMed ID: 7730016
[TBL] [Abstract][Full Text] [Related]
38. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
39. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice.
Knutson KL; Dang Y; Lu H; Lukas J; Almand B; Gad E; Azeke E; Disis ML
J Immunol; 2006 Jul; 177(1):84-91. PubMed ID: 16785502
[TBL] [Abstract][Full Text] [Related]
40. Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
Byrne A; Savas P; Sant S; Li R; Virassamy B; Luen SJ; Beavis PA; Mackay LK; Neeson PJ; Loi S
Nat Rev Clin Oncol; 2020 Jun; 17(6):341-348. PubMed ID: 32112054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
